These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11963640)

  • 1. [Physiologic and therapeutic importance of serotonin and the serotonergic system].
    Molderings GJ
    Arzneimittelforschung; 2002; 52(3):145-54. PubMed ID: 11963640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiological, pathophysiological and therapeutic impact of the enteric serotonergic system.
    Molderings GJ
    Arzneimittelforschung; 2012 Apr; 62(4):157-66. PubMed ID: 22438071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
    Moulignier A
    Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.
    Johanson JF
    Neurogastroenterol Motil; 2004 Dec; 16(6):701-11. PubMed ID: 15601419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin and its role in colonic function and in gastrointestinal disorders.
    Costedio MM; Hyman N; Mawe GM
    Dis Colon Rectum; 2007 Mar; 50(3):376-88. PubMed ID: 17195902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent insights into the pathogenesis of abdominal symptoms in functional bowel disorders].
    Cervio E; Rondanelli M; Balestra B; Dellabianca A; Agazzi A; Giacosa A; Tonini M
    Recenti Prog Med; 2007 Feb; 98(2):69-73. PubMed ID: 17439064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT4 receptor agonists: similar but not the same.
    De Maeyer JH; Lefebvre RA; Schuurkes JA
    Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for using serotonergic agents to treat irritable bowel syndrome.
    Baker DE
    Am J Health Syst Pharm; 2005 Apr; 62(7):700-11; quiz 712-3. PubMed ID: 15790796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of serotonin in the pathophysiology of irritable bowel syndrome.
    Crowell MD
    Am J Manag Care; 2001 Jul; 7(8 Suppl):S252-60. PubMed ID: 11474910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-hydroxytryptamine and the gastrointestinal tract: where next?
    Sanger GJ
    Trends Pharmacol Sci; 2008 Sep; 29(9):465-71. PubMed ID: 19086255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irritable bowel syndrome: new pharmaceutical approaches to treatment.
    Farthing MJ
    Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
    Gershon MD; Tack J
    Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic drugs--a possible role in the treatment of psoriasis?
    Thorslund K; Nordlind K
    Drug News Perspect; 2007 Oct; 20(8):521-5. PubMed ID: 18080039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.
    de Boer SF; Koolhaas JM
    Eur J Pharmacol; 2005 Dec; 526(1-3):125-39. PubMed ID: 16310183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of serotonin in the pathophysiology of the irritable bowel syndrome.
    Crowell MD
    Br J Pharmacol; 2004 Apr; 141(8):1285-93. PubMed ID: 15100164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
    Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
    Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors.
    Massot O; Rousselle JC; Fillion MP; Grimaldi B; Cloëz-Tayarani I; Fugelli A; Prudhomme N; Seguin L; Rousseau B; Plantefol M; Hen R; Fillion G
    Mol Pharmacol; 1996 Oct; 50(4):752-62. PubMed ID: 8863819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV; Buccafusco JJ; Wilson C
    Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irritable bowel syndrome: new and emerging therapies.
    Harris LA; Chang L
    Curr Opin Gastroenterol; 2006 Mar; 22(2):128-35. PubMed ID: 16462168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.